VRCA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
5.9M
+16.7%
5.0M
-1.4%
5.1M
-64.5%
14.3M
+12.9%
12.7M
Cost of Revenue
878.0K
-1.2%
889.0K
-36.5%
1.4M
+26.3%
1.1M
+124.5%
494.0K
Gross Profit
5.0M
+20.6%
4.1M
+12.0%
3.7M
-72.1%
13.2M
+8.4%
12.2M
Operating Expenses
18.1M
+30.6%
13.8M
+30.2%
10.6M
-8.4%
11.6M
+8.5%
10.7M
R&D
6.0M
+56.3%
3.9M
+53.2%
2.5M
+14.3%
2.2M
+19.4%
1.8M
SG&A
10.3M
+3.6%
10.0M
+23.1%
8.1M
-13.7%
9.4M
+6.2%
8.9M
Operating Income
-13097000
-34.8%
-9715000
-39.9%
-6946000
-526.9%
1.6M
+7.7%
1.5M
EBITDA
-11384000
-17.4%
-9698000
-39.9%
-6932000
-520.1%
1.6M
+6.2%
1.6M
Net Income
-13153000
-35.9%
-9682000
-19.9%
-8074000
-2846.7%
-274000
-234.3%
204.0K
EPS (Basic)
$-0.62
-37.8%
$-0.45
+21.1%
$-0.57
-1800.0%
$-0.03
-250.0%
$0.02
EPS (Diluted)
$-0.62
-37.8%
$-0.45
+21.1%
$-0.57
-1800.0%
$-0.03
-250.0%
$0.02
Shares (Diluted)
21.3M
+0.0%
21.3M
+50.6%
14.1M
+49.1%
9.5M
-0.0%
9.5M
Verrica Pharmaceuticals (VRCA) โ€” Financials